Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 10/20 | 1.00 |
| ▸ | PDE7B | Q9NP56 | 5/20 | 1.00 |
| ▸ | PDE8A | O60658 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.34 |
| ▸ | AKT1 | P31749 | 3/20 | 0.33 |
| ▸ | AKT2 | P31751 | 3/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL101130 | 1.00 | PDE7A (1.00) | PDE7APDE7BPDE8AALDH1A1NPSR1 | |
| SCHEMBL100403 | 0.89 | PDE7A (0.81) | PDE7APDE7BPDE8AALDH1A1NPSR1 | |
| SCHEMBL30837875 | 0.89 | PDE7A (0.81) | PDE7APDE7BPDE8AALDH1A1NPSR1 | |
| SCHEMBL99919 | 0.88 | PDE7A (0.78) | PDE7APDE7BPDE8AALDH1A1NPSR1 | |
| SCHEMBL99946 | 0.86 | PDE7A (0.76) | PDE7APDE7BPDE8AALDH1A1NPSR1 | |
| SCHEMBL100798 | 0.86 | PDE7A (0.76) | PDE7APDE7BPDE8ANPSR1 | |
| SCHEMBL100353 | 0.83 | PDE7A (0.71) | PDE7APDE7BPDE8ANPSR1 | |
| SCHEMBL30837769 | 0.83 | PDE7A (0.71) | PDE7APDE7BPDE8ANPSR1 | |
| SCHEMBL100681 | 0.83 | PDE7A (0.78) | PDE7APDE7BPDE8ANPSR1C5AR1 | |
| SCHEMBL100794 | 0.83 | PDE7A (0.78) | PDE7APDE7BPDE8AALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | MITODICURE GMBH (DE) | 2026-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | PDE5A, PDE4C, PDE12 | PDE7A 5/4885PDE7B 14/4885PDE8A 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.